Rahnab Pharmed is a specialized healthcare and pharmaceutical holding that, relying on an ecosystem of specialized knowledge-based enterprises, has forged an end-to-end integrated value chain spanning raw material and plasma supply, R&D, advanced pharmaceuticals, biologics, vaccines, novel therapeutic formulations, and cell therapy. Our strategy is founded upon creating synergy across group companies, advancing cutting-edge biotechnology, localizing strategic healthcare products, and meeting the critical needs of the national healthcare system.
The operations of Rahnab Pharmed group companies span across diverse sectors of the healthcare and pharmaceutical value chain. This integrated structure empowers Rahnab Pharmed to foster vital synergies among group companies, accelerating the translation of scientific discoveries into effective, life-saving therapeutics for patients.
Our strategic focus is anchored in forging synergy among group subsidiaries, scaling state-of-the-art biotechnology, localizing sovereign therapeutics, and safeguarding national healthcare resilience. At Rahnab Pharmed, we believe the future of the biopharma industry belongs to scientific excellence, sustainable manufacturing, and multidisciplinary collaboration.
From raw material and plasma collection to advanced therapeutics and finished formulations.
Strategic investment in biotechnology, vaccines, cell therapy, and novel biologicals.
Dedicated focus on localizing strategic pharmaceutical products and reducing import dependence.
Targeted alignment and operational integration across all subsidiaries in the healthcare value chain.
Directly fulfilling critical national healthcare demands and ensuring equitable patient access.
Integrating full supply chain processes, from plasma collection to advanced cell therapy and strategic vaccine development at the highest international standards.
Plasma Collection & Fractionation
Human plasma collection through a network of eight apheresis centers and production of vital plasma-derived medicines including Albumin, IVIG, Fibrinogen, and Factor VIII.
Insulin & Critical Therapeutics
Developing manufacturing capacity for eight types of insulin required by the country to reduce import dependency and secure medication for diabetic patients.
Recombinant Vaccines & Prevention
Manufacturing Papilloguard and Pneumoguard vaccines and developing Zonaguard to prevent diseases and strengthen national immunization infrastructure.
Cell Therapy & CAR-T Platforms
Developing and manufacturing CAR-T cells and localizing advanced cellular therapies; advancing toward treating intractable diseases with next-generation technologies.
Hyperimmune Sera & Antivenoms
Producing approximately 70% of Iran's scorpion and snake antivenom requirements and providing emergency therapeutic sera for venomous envenomation.
Biotech Acceleration & Venture Incubation
Identifying scientific potential and translating it into scalable products; acting as the essential bridge connecting knowledge, technology, and the modern biopharma industry.
Integrated, merit-based corporate governance orchestrating national healthcare resilience.
Highest policy-making and strategic governance body
Independent financial supervision, internal controls & risk assessment
Executive command and operational governance across all subsidiaries
Venture capital & portfolio governance
Strategic formulation & industrial project control
Financial discipline, accounting & human resources
Patent protection, corporate contracts & IP registration
At Rahnab Pharmed, we believe advanced biomanufacturing facilities are meaningless without brilliant, dedicated minds. Our holding ecosystem hosts an active network of over 1,400 researchers and biotechnology pioneers.
Synergistic specialized enterprises across the integrated healthcare and biopharmaceutical value chain
Development & Production of Plasma-Derived Therapeutics and Advanced Biologics
First Node in the Plasma Value Chain — Network of 8 Centers Nationwide
A Decisive Step Toward Insulin Self-Sufficiency and Novel Therapeutics
Manufacturing Over 70% of National Emergency Antivenoms & Hyperimmune Sera
Specialized Biopharmaceutical Accelerator & Translational Bridge
Pioneer in Cellular Therapeutics, CAR-T Cell Platforms & ATMP in Iran
Development & Production of Papilloguard, Pneumoguard and Zonaguard Vaccines
Rahnab Pharmed direct communications desk is open to business inquiries, technology transfers, and collaborative ventures.